Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (NCT06057402)
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
🩺 Plain-English Summary (8th-Grade Level)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (3 items).
Location: UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
- UC Irvine Health — Orange, California
- UCI Health — Orange, California
- UCHealth Poudre Valley Hospital — Fort Collins, Colorado
- UCHealth Harmony — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- Longs Peak Hospital — Longmont, Colorado
- UCHealth Longs Peak Medical Center — Longmont, Colorado
- UCHealth - Medical Center of the Rockies — Loveland, Colorado
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
- University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics - Griffin Cancer Research Building — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- St. David's South Austin Medical Center — Austin, Texas
- Epworth Freemasons — Melbourne, Victoria
- Epworth Hospital — Richmond, Victoria
- Slade Pharmacy — Richmond, Victoria
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- McGill University Health Centre — Montreal, Quebec
- Peking University Third Hospital — Beijing, Beijing Municipality
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: Participants will receive elranatamab.
More studies in Multiple Myeloma
- Registry for Adults With Plasma Cell Disorders (PCD's) — Chapel Hill, North Carolina
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma — Mobile, Alabama
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events — San Francisco, California
- A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients — Goodyear, Arizona
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) — Miami, Florida
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma — La Crosse, Wisconsin
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.